Vall d'Hebron Institute of Oncology (VHIO) at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Vall d'Hebron Institute of Oncology (VHIO) takes part in 18 sessions at ESMO 2026 in Madrid. Its program centres on early drug development and precision medicine, from tumour-agnostic trial design and the genomics of metastatic cancer to a bispecific antibody for immunotherapy-resistant tumours. Other sessions cover radioligand therapy for neuroendocrine tumours, invasive lobular breast cancer, CAR-T cell therapy and artificial intelligence in tumour boards.
| Organization | ESMO 2026 Attendance |
|---|---|
Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Spain | |
Translational cancer research institute on the campus of Vall d'Hebron University Hospital in Barcelona, Spain, running early-phase trials. | Talk Fri Oct 23 13:30 Chair Fri Oct 23 13:30–14:45 Talk Fri Oct 23 13:50–14:05 Medical oncology perspective Breast cancer Abstract Fri Oct 23 14:15–14:25 Chair Fri Oct 23 16:15–17:45 Raising the bar for tumor-agnostic studies Biomarkers & precision oncology Chair Fri Oct 23 16:15–17:45 The evolving standards in the management of chronic lymphocytic leukemia Haematological malignancies Talk Fri Oct 23 17:15–17:35 From hematologic success to solid tumor challenges: CAR-T therapy and T-cell transformation risk Haematological malignancies Chair Sat Oct 24 08:30–10:00 Metastases: Understanding and targeting cancer spread Biomarkers & precision oncology Talk Sat Oct 24 08:30–08:50 Understanding the genomic landscape of metastatic cancer and its therapeutic potential Biomarkers & precision oncology Chair Sat Oct 24 14:45–16:15 Emerging therapies in endocrine and neuroendocrine neoplasms Sarcoma, CNS, head & neck and rare cancers Abstract Sat Oct 24 15:37–15:47 Satellite Sat Oct 24 19:23–19:58 Navigating the NET treatment journey Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Talk Sun Oct 25 08:35–08:55 Talk Sun Oct 25 10:15–10:30 Chair Sun Oct 25 14:45–16:15 Toxicities of immunotherapies beyond immune checkpoints Nursing & supportive care Talk Sun Oct 25 15:05–15:25 Current landscape of the use of radioligands in gastroenteropancreatic Neuroendocrine neoplasms Sarcoma, CNS, head & neck and rare cancers Talk Sun Oct 25 15:15–15:30 Chair Mon Oct 26 08:30–10:00 Rapid oral: Sarcoma Sarcoma, CNS, head & neck and rare cancers Abstract Mon Oct 26 09:12–09:24 Invited Discussant 3720RO, 3721RO and 3722RO Sarcoma, CNS, head & neck and rare cancers Chair Mon Oct 26 10:15–11:45 Abstract Mon Oct 26 11:00–11:05 Talk Mon Oct 26 15:15–15:30 |
Instantly find 20 buyers from Vall d'Hebron Institute of Oncology (VHIO)
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction